Silexion Therapeutics (SLXN) News Today $3.52 -0.04 (-1.12%) Closing price 10/17/2025 03:59 PM EasternExtended Trading$3.57 +0.05 (+1.42%) As of 10/17/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLXN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Silexion Therapeutics Unveils Promising SIL204 DataOctober 2, 2025 | theglobeandmail.comSilexion Therapeutics announces new data in SIL204September 30, 2025 | msn.comSilexion Therapeutics Reports Promising Preclinical Results for SIL204 as a Pan-KRAS Inhibitor Across Multiple Cancer TypesSeptember 30, 2025 | quiverquant.comQSilexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric CancerSeptember 30, 2025 | globenewswire.comSilexion Therapeutics Enters Market Offering AgreementSeptember 26, 2025 | tipranks.comSilexion Therapeutics Regains Nasdaq Compliance, Moving Forward with Clinical Trials for KRAS-Driven CancersSeptember 25, 2025 | quiverquant.comQSilexion Therapeutics Regains Compliance with Nasdaq Listing RequirementsSeptember 25, 2025 | globenewswire.comSilexion Therapeutics Converts Debt to Equity for Nasdaq ComplianceSeptember 15, 2025 | tipranks.comSilexion Therapeutics prices 1.5M shares at $4.00 in public offeringSeptember 11, 2025 | msn.comSilexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer DataSeptember 11, 2025 | benzinga.comSilexion Therapeutics Announces Pricing of $6.0 Million Public OfferingSeptember 11, 2025 | globenewswire.comSilexion stock soars 400% after positive pancreatic cancer drug dataSeptember 11, 2025 | uk.investing.comSilexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic AdministrationSeptember 11, 2025 | markets.businessinsider.comSilexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic AdministrationSeptember 11, 2025 | globenewswire.comSilexion Therapeutics selects AMS as CRO for SIL204 Phase 2/3 trialsSeptember 4, 2025 | msn.comSilexion Therapeutics Selects AMS Advanced Medical Services as CRO to Support SIL204 Phase 2/3 Clinical Trials Following Promising Preclinical ResultsSeptember 4, 2025 | quiverquant.comQSilexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204September 4, 2025 | globenewswire.comSilexion Therapeutics Corp. to Present at 27th Annual H.C. Wainwright Global Investment ConferenceSeptember 2, 2025 | quiverquant.comQSilexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment ConferenceSeptember 2, 2025 | globenewswire.comSilexion Therapeutics Executes Reverse Stock SplitAugust 22, 2025 | msn.comSilexion Therapeutics Increases Authorized Share CapitalAugust 19, 2025 | tipranks.comSilexion Therapeutics Corp: Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 13, 2025 | finanznachrichten.deSilexion Therapeutics Corp. Reports Second Quarter 2025 Financial Results and Preclinical Advancements in RNAi Therapies for KRAS-Driven CancersAugust 12, 2025 | quiverquant.comQSilexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | globenewswire.comSilexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross ProceedsJuly 31, 2025 | globenewswire.comSilexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS MutationJuly 31, 2025 | globenewswire.comSilexion Therapeutics Holds Annual General MeetingJuly 17, 2025 | theglobeandmail.comSilexion Therapeutics Announces 1-for-15 Reverse Share SplitJuly 16, 2025 | globenewswire.comSilexion Therapeutics Corp. Reports Positive Preclinical Data for ...July 11, 2025 | nasdaq.comSilexion Therapeutics Announces Positive Results in Preclinical Study ...July 11, 2025 | morningstar.comMSilexion Therapeutics receives Nasdaq panel approval for continued listingJuly 9, 2025 | uk.investing.comSilexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell LinesJuly 9, 2025 | globenewswire.comSilexion Therapeutics announces preclinical results on SIL204May 30, 2025 | finance.yahoo.comSilexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal TumorsMay 30, 2025 | msn.comSilexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung CancersMay 29, 2025 | finance.yahoo.comSilexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant CancersMay 23, 2025 | nasdaq.comSilexion Therapeutics Receives Nasdaq Delisting NoticeMay 23, 2025 | tipranks.comPESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer TreatmentMay 22, 2025 | globenewswire.comSilexion Therapeutics Corporation Registered ShsMay 22, 2025 | markets.businessinsider.comSilexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung CancerMay 21, 2025 | finance.yahoo.comSilexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung CancerMay 21, 2025 | globenewswire.comSilexion Therapeutics Corp: Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | finanznachrichten.deSilexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comSilexion Therapeutics enters collaboration with CatalentApril 25, 2025 | markets.businessinsider.comSilexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing ActivitiesApril 23, 2025 | globenewswire.comSilexion Therapeutics announces expanded development plan for SIL204March 28, 2025 | markets.businessinsider.comSilexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical DataMarch 28, 2025 | globenewswire.comSilexion announces completion of expanded development plan for SIL204March 21, 2025 | markets.businessinsider.comSilexion Therapeutics price target lowered to $5 from $9 at MaximMarch 21, 2025 | markets.businessinsider.comSilexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer ConferenceMarch 21, 2025 | globenewswire.com Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLXN Media Mentions By Week SLXN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLXN News Sentiment▼1.000.46▲Average Medical News Sentiment SLXN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLXN Articles This Week▼11▲SLXN Articles Average Week Get the Latest News and Ratings for SLXN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Silexion Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Tempest Therapeutics News CalciMedica News BioAtla News Estrella Immunopharma News Neuphoria Therapeutics News Senti Biosciences News PDS Biotechnology News FibroGen News ZIVO Bioscience News RenovoRx News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLXN) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLXN with Qtrade Free SLXN Stock Alerts